<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04078698</url>
  </required_header>
  <id_info>
    <org_study_id>TA-IA-03-INT</org_study_id>
    <nct_id>NCT04078698</nct_id>
  </id_info>
  <brief_title>Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorbers GLOBAFFIN® and LIGASORB® and IgE Immunoadsorber IgEnio® in Clinical Routine (SEPIAR)</brief_title>
  <acronym>SEPIAR</acronym>
  <official_title>Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorbers GLOBAFFIN® and LIGASORB® and IgE Immunoadsorber IgEnio® in Clinical Routine (SEPIAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fresenius Medical Care Deutschland GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fresenius Medical Care Deutschland GmbH</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Documentation of the safety and effectiveness profile of the CE-labelled immunoadsorbers&#xD;
      GLOBAFFIN®, LIGASORB® and IgEnio® in clinical routine according to their intended use.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of the study is the documentation of the safety and effectiveness profile of&#xD;
      the CE-labeled immunoadsorbers GLOBAFFIN®, LIGASORB® and IgEnio® in clinical routine&#xD;
      according to their intended use over a time peroid of 5 years.&#xD;
&#xD;
      The primary objective for the IgG adsorber GLOBAFFIN® and LIGASORB® is the estimation of the&#xD;
      mean relative reduction in total IgG from pre- to post-treatment per treatment session. The&#xD;
      primary objective for the IgE adsorber IgEnio® is the estimation of the mean relative&#xD;
      reduction in total IgE from pre- to post-treatment per treatment session.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 5, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative reduction in total IgG from pre- to post-treatment (for GLOBAFFIN and LIGASORB treatments)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative reduction in total IgE from pre- to post-treatment(for IgEnio treatments)</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean relative reduction in disease-specific IgG, total IgM and total IgA</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical effect of the treatment measured by the physician's judgement as well as indication specific scores</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events and serious adverse events during the treatment, reported incidents, device deficiencies and handling problems</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Reduction of laboratory safety parameters</measure>
    <time_frame>5 years</time_frame>
  </other_outcome>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Autoimmune Diseases</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoadsorbers GLOBAFFIN®, LIGASORB® and IgEnio®</intervention_name>
    <description>Documentation of the treatment with one of the immunoadsorbers GLOBAFFIN®, LIGASORB® or IgEnio® depending on the patient's underlying disease</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with one of the immunoadsorbers GLOBAFFIN®, LIGASORB® or IgEnio® according&#xD;
        to the intended use and to clinical routine protocols or with planned treatments&#xD;
        (first-use) with one of the immunoadsorbers according to the intended use and to clinical&#xD;
        routine protocols.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  Informed consent signed and dated by study patient and investigator/authorised&#xD;
             physician&#xD;
&#xD;
          -  Ability to understand the nature and requirements of the study&#xD;
&#xD;
          -  Treatment with one of the immunoadsorber systems GLOBAFFIN®, LIGASORB®, IgEnio®&#xD;
             according to the intended use.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        General:&#xD;
&#xD;
          -  Any condition which could interfere with the patient's ability to comply with the&#xD;
             study&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Participation in an interventional clinical study during the preceding 30 days.&#xD;
&#xD;
          -  Participation in an interventional clinical study with pharmacological active&#xD;
             substances (e.g. therapeutic antibodies) during the preceding 60 days.&#xD;
&#xD;
          -  Any deviation from the intended use&#xD;
&#xD;
        Study-specific:&#xD;
&#xD;
        Any contraindication listed in the valid instruction for use:&#xD;
&#xD;
          -  Hypersensitivity or allergy against any materials used in either the immunoadsorber&#xD;
             column or the extracorporeal circuit&#xD;
&#xD;
          -  Inability to withstand the stress of an extracorporeal treatment procedure due to&#xD;
             their age, their physical developments or their clinical constitution&#xD;
&#xD;
          -  Previously demonstrated hypersensitivity associated with therapeutic apheresis&#xD;
&#xD;
          -  No suitable anticoagulation treatment, such as due to known hypersensitivity to&#xD;
             heparin or ACD-A&#xD;
&#xD;
          -  Haemorrhagic diathesis in which extracorporeal apheresis procedures and&#xD;
             anticoagulation performed have a high bleeding hazard&#xD;
&#xD;
          -  Severe cardiovascular disease, so that extracorporeal treatment is not possible&#xD;
&#xD;
          -  Acute, systemic infection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan T. Kielstein, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Städtisches Klinikum Braunschweig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuela Stauss-Grabo, Dr.</last_name>
    <phone>+49 6172 609 5248</phone>
    <email>Manuela.Stauss-Grabo@fmc-ag.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mareike Giefer</last_name>
    <phone>+49 6172 609 2263</phone>
    <email>Mareike.Giefer@fmc-ag.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Städtisches Klinikum Braunschweig</name>
      <address>
        <city>Braunschweig</city>
        <state>Niedersachsen</state>
        <zip>38126</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan T. Kielstein, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Diakonissenkrankenhaus Flensburg</name>
      <address>
        <city>Flensburg</city>
        <zip>24939</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W Ries, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>September 2, 2019</study_first_submitted>
  <study_first_submitted_qc>September 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>August 5, 2020</last_update_submitted>
  <last_update_submitted_qc>August 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic apheresis</keyword>
  <keyword>Immune apheresis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autoimmune Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

